Grover SA - Search Results

1

Relationship between dietary intake and coronary heart disease mortality: lipid research clinics prevalence follow-up study.

Esrey KL, Joseph L, Grover SA. Esrey KL, et al. Among authors: grover sa. J Clin Epidemiol. 1996 Feb;49(2):211-6. doi: 10.1016/0895-4356(95)00066-6. J Clin Epidemiol. 1996. PMID: 8606322

2

Health-related quality of life with coronary heart disease prevention and treatment.

Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA; Canadian Collaborative Cardiac Assessment Group. Lalonde L, et al. Among authors: grover sa. J Clin Epidemiol. 2001 Oct;54(10):1011-8. doi: 10.1016/s0895-4356(01)00361-4. J Clin Epidemiol. 2001. PMID: 11576812

3

Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Grover SA, et al. Arch Intern Med. 1998 Mar 23;158(6):655-62. doi: 10.1001/archinte.158.6.655. Arch Intern Med. 1998. PMID: 9521231

4

Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study.

Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Grover SA, et al. BMJ. 1995 Apr 15;310(6985):975-8. doi: 10.1136/bmj.310.6985.975. BMJ. 1995. PMID: 7728035 Free PMC article.

5

How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?

Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR. Grover SA, et al. Diabetes Care. 2001 Jan;24(1):45-50. doi: 10.2337/diacare.24.1.45. Diabetes Care. 2001. PMID: 11194239

6

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Grover SA, Coupal L, Paquet S, Zowall H. Grover SA, et al. Arch Intern Med. 1999 Mar 22;159(6):593-600. doi: 10.1001/archinte.159.6.593. Arch Intern Med. 1999. PMID: 10090116

7

Flexible modeling of the effects of serum cholesterol on coronary heart disease mortality.

Abrahamowicz M, du Berger R, Grover SA. Abrahamowicz M, et al. Among authors: grover sa. Am J Epidemiol. 1997 Apr 15;145(8):714-29. doi: 10.1093/aje/145.8.714. Am J Epidemiol. 1997. PMID: 9125998

8

Modifying serum lipids to prevent coronary heart disease: do we have a consensus?

Grover SA. Grover SA. Cardiovasc Drugs Ther. 1993 Nov;7(5):761-5. doi: 10.1007/BF00878927. Cardiovasc Drugs Ther. 1993. PMID: 8110617

9

Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort.

Grover SA, Palmer CS, Coupal L. Grover SA, et al. Arch Intern Med. 1994 Mar 28;154(6):679-84. Arch Intern Med. 1994. PMID: 8129502

10

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?

Grover SA, Coupal L, Zowall H, Dorais M. Grover SA, et al. Circulation. 2000 Aug 15;102(7):722-7. doi: 10.1161/01.cir.102.7.722. Circulation. 2000. PMID: 10942738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results